New Hope for Atopic Dermatitis Sufferers: When First Treatments Fail
For millions worldwide battling moderate-to-severe atopic dermatitis (eczema), finding effective long-term relief can be a frustrating journey. A recent study, the ADapt trial, offers a promising development: a viable option when initial biologic treatments, like Dupilumab, don’t deliver the desired results. Korean pharmaceutical company Lilly recently announced findings demonstrating the efficacy and safety of ‘Ebglyss’ (lebrikizumab) as a switch therapy for these patients.
The Challenge of Biologic Treatment Failure
Atopic dermatitis is a complex condition driven by multiple immune pathways. This means what works for one person may not work for another. Current guidelines recommend systemic treatments, including biologics, for moderate-to-severe cases. However, a significant portion of patients – approximately 18-20% – discontinue biologic therapy within 3-4 years. The primary reasons? Loss of efficacy (26-40%) and adverse reactions (20%). This highlights the critical need for alternative treatment options.
“The reality is, patients don’t always respond to the first biologic they try,” explains Dr. Iyang Won, President of the Korean Dermatological Association. “Different biologics target different parts of the immune system. Switching therapies can be crucial, and the ADapt study provides scientific evidence supporting this approach.”
Ebglyss: A New Mechanism, Proven Results
Ebglyss, approved in South Korea in August 2024 and slated for national health insurance coverage for severe cases from July 2025, represents a new class of biologic targeting the IL-13 cytokine. The ADapt trial, an open-label Phase 3b study conducted in the US, involved 86 patients who had stopped Dupilumab due to insufficient response, side effects, or other reasons.
The results were encouraging. 68.6% of patients completed 16 weeks of Ebglyss treatment, and 60.5% completed 24 weeks. Crucially, 57.4% achieved an EASI 75 response (a 75% improvement in eczema severity) at 16 weeks, rising to 60.0% at 24 weeks. Even patients who hadn’t responded adequately to Dupilumab saw significant improvement, with 50.0% achieving EASI 75 at 24 weeks after switching to Ebglyss.
Did you know? EASI (Eczema Area and Severity Index) is a commonly used scoring system to measure the severity of atopic dermatitis. A lower score indicates less severe disease.
Beyond Skin Deep: Improvements in Itch and Quality of Life
The benefits of switching to Ebglyss extended beyond just skin lesions. Patients reported significant improvements in itch and quality of life. Over 61% experienced a reduction of at least 4 points on the Numerical Rating Scale for itch, and 83% reported a 4-point or greater improvement in their Dermatological Life Quality Index (DLQI) scores. An impressive 94.5% of patients expressed positive feelings about the new treatment.
Furthermore, patients experienced improvements in sleep disturbance related to itch, skin pain, and facial skin lesions – consistent with findings from previous Ebglyss trials. Importantly, patients who had stopped Dupilumab due to eye-related side effects, facial dermatitis, or inflammatory joint pain did not experience the same issues with Ebglyss.
The Future of Atopic Dermatitis Treatment: Personalized Approaches
The ADapt trial underscores a growing trend in atopic dermatitis management: personalized medicine. The “one-size-fits-all” approach is becoming obsolete. Understanding the specific immune pathways driving a patient’s eczema is crucial for selecting the most effective treatment.
Pro Tip: If your current atopic dermatitis treatment isn’t working, don’t hesitate to discuss alternative options with your dermatologist. There are now multiple biologics available, each with a unique mechanism of action.
Looking ahead, several key developments are likely to shape the future of atopic dermatitis care:
- Biomarker-Driven Treatment Selection: Advances in biomarker research will allow doctors to identify which patients are most likely to respond to specific therapies.
- Combination Therapies: Combining different biologics or biologics with topical treatments may offer synergistic benefits.
- Oral Therapies: Research into new oral medications targeting specific immune pathways is ongoing, potentially offering a more convenient treatment option.
- Expanded Access to Treatment: Advocacy efforts, like those highlighted by Dr. Won, are crucial to ensure that patients have access to the treatments they need, regardless of cost or insurance coverage.
The current restrictive reimbursement criteria in some countries, including South Korea, which don’t allow for switching between biologics, are a significant barrier to optimal care. Changes to these policies are urgently needed.
FAQ
- What is Ebglyss? Ebglyss (lebrikizumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis.
- What is a switch therapy? Switch therapy involves changing from one biologic medication to another.
- Is Ebglyss safe? The ADapt trial showed Ebglyss to have a consistent safety profile, with most side effects being mild to moderate.
- Will Ebglyss be covered by insurance? Ebglyss is slated for national health insurance coverage in South Korea from July 2025. Coverage in other countries will vary.
This research represents a significant step forward in providing more effective and personalized treatment options for individuals living with atopic dermatitis. The ability to switch therapies when initial treatments fail offers renewed hope for long-term relief and improved quality of life.
Want to learn more about managing atopic dermatitis? Visit the National Eczema Association website for resources, support, and the latest research.
Share your experiences with atopic dermatitis in the comments below! What treatments have worked for you, and what challenges have you faced?
Worth a look